Biotest（BIO3）株式概要バイオテスト・アクチェンゲゼルシャフトは、生物学的およびバイオ技術的医薬品の開発、製造、販売をドイツ国内および国際的に行っている。 詳細BIO3 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性2/6配当金0/6リスク分析利払いは収益で十分にカバーされない 株式の流動性は非常に低い すべてのリスクチェックを見るBIO3 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€28.4064.9% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-54m1b2016201920222025202620282031Revenue €1.0bEarnings €190.6mAdvancedSet Fair ValueView all narrativesBiotest Aktiengesellschaft 競合他社FormyconSymbol: XTRA:FYBMarket cap: €367.6mDextech MedicalSymbol: DB:LQ0Market cap: €185.8mGenetic AnalysisSymbol: DB:8V8Market cap: €42.7mHeidelberg PharmaSymbol: XTRA:HPHAMarket cap: €127.3m価格と性能株価の高値、安値、推移の概要Biotest過去の株価現在の株価€28.4052週高値€31.8052週安値€25.00ベータ0.0811ヶ月の変化0%3ヶ月変化-3.40%1年変化4.80%3年間の変化-19.32%5年間の変化13.15%IPOからの変化350.63%最新ニュースお知らせ • May 23Biotest Aktiengesellschaft announces Annual dividend, payable on July 07, 2025Biotest Aktiengesellschaft announced Annual dividend of EUR 0.0400 per share payable on July 07, 2025, ex-date on July 03, 2025 and record date on July 04, 2025.お知らせ • May 22Biotest Aktiengesellschaft, Annual General Meeting, Jul 02, 2025Biotest Aktiengesellschaft, Annual General Meeting, Jul 02, 2025, at 10:30 W. Europe Standard Time.Reported Earnings • May 14First quarter 2025 earnings released: €0.55 loss per share (vs €0.74 profit in 1Q 2024)First quarter 2025 results: €0.55 loss per share (down from €0.74 profit in 1Q 2024). Revenue: €124.2m (down 42% from 1Q 2024). Net loss: €21.4m (down 173% from profit in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.お知らせ • Apr 02Grifols Biotest Holdings GmbH, proposed to acquire remaining 28.31% stake in Biotest Aktiengesellschaft (XTRA:BIO3) from shareholders for approximately €340 million.Grifols Biotest Holdings GmbH, proposed to acquire remaining 28.31% stake in Biotest Aktiengesellschaft (XTRA:BIO3) from shareholders for approximately €340 million on March 31, 2025. The Management Board and the Supervisory Board will carefully review the offer document for the public delisting acquisition offer and issue a joint reasoned statement in accordance with Section 27 of the German Securities Acquisition and Takeover Act. The delisting agreement contains provisions that Grifols, S.A. intends to support Biotest AG in an economically reasonable manner. After the revocation of the stock exchange admission becomes effective, the shares of Biotest AG will no longer be admitted to trading on a domestic regulated market or a comparable market abroad. According to the provisions of the delisting agreement, Grifols Biotest Holdings GmbH, a 100% subsidiary of Grifols, S.A., will make an unconditional public delisting acquisition offer to the shareholders of Biotest AG to acquire all ordinary and preference shares of Biotest AG that are not already held by Grifols Biotest Holdings GmbH, in exchange for a cash consideration of €43.00 per Biotest ordinary share and €30.00 per Biotest preference share, subject to adjustments due to legal provisions. The terms and conditions of the delisting offer will be communicated in the offer document ("Offer Document") to be prepared by Grifols and to be examined by the German federal financial supervisory. Banco Santander, S.A. acted as a financial advisor to Biotest Aktiengesellschaft.Reported Earnings • Apr 01Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: EPS: €0.66 (down from €3.21 in FY 2023). Revenue: €726.2m (up 6.1% from FY 2023). Net income: €26.4m (down 79% from FY 2023). Profit margin: 3.6% (down from 19% in FY 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.お知らせ • Mar 18+ 1 more updateBiotest Aktiengesellschaft to Report Q3, 2025 Results on Nov 10, 2025Biotest Aktiengesellschaft announced that they will report Q3, 2025 results on Nov 10, 2025最新情報をもっと見るRecent updatesお知らせ • May 23Biotest Aktiengesellschaft announces Annual dividend, payable on July 07, 2025Biotest Aktiengesellschaft announced Annual dividend of EUR 0.0400 per share payable on July 07, 2025, ex-date on July 03, 2025 and record date on July 04, 2025.お知らせ • May 22Biotest Aktiengesellschaft, Annual General Meeting, Jul 02, 2025Biotest Aktiengesellschaft, Annual General Meeting, Jul 02, 2025, at 10:30 W. Europe Standard Time.Reported Earnings • May 14First quarter 2025 earnings released: €0.55 loss per share (vs €0.74 profit in 1Q 2024)First quarter 2025 results: €0.55 loss per share (down from €0.74 profit in 1Q 2024). Revenue: €124.2m (down 42% from 1Q 2024). Net loss: €21.4m (down 173% from profit in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.お知らせ • Apr 02Grifols Biotest Holdings GmbH, proposed to acquire remaining 28.31% stake in Biotest Aktiengesellschaft (XTRA:BIO3) from shareholders for approximately €340 million.Grifols Biotest Holdings GmbH, proposed to acquire remaining 28.31% stake in Biotest Aktiengesellschaft (XTRA:BIO3) from shareholders for approximately €340 million on March 31, 2025. The Management Board and the Supervisory Board will carefully review the offer document for the public delisting acquisition offer and issue a joint reasoned statement in accordance with Section 27 of the German Securities Acquisition and Takeover Act. The delisting agreement contains provisions that Grifols, S.A. intends to support Biotest AG in an economically reasonable manner. After the revocation of the stock exchange admission becomes effective, the shares of Biotest AG will no longer be admitted to trading on a domestic regulated market or a comparable market abroad. According to the provisions of the delisting agreement, Grifols Biotest Holdings GmbH, a 100% subsidiary of Grifols, S.A., will make an unconditional public delisting acquisition offer to the shareholders of Biotest AG to acquire all ordinary and preference shares of Biotest AG that are not already held by Grifols Biotest Holdings GmbH, in exchange for a cash consideration of €43.00 per Biotest ordinary share and €30.00 per Biotest preference share, subject to adjustments due to legal provisions. The terms and conditions of the delisting offer will be communicated in the offer document ("Offer Document") to be prepared by Grifols and to be examined by the German federal financial supervisory. Banco Santander, S.A. acted as a financial advisor to Biotest Aktiengesellschaft.Reported Earnings • Apr 01Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: EPS: €0.66 (down from €3.21 in FY 2023). Revenue: €726.2m (up 6.1% from FY 2023). Net income: €26.4m (down 79% from FY 2023). Profit margin: 3.6% (down from 19% in FY 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.お知らせ • Mar 18+ 1 more updateBiotest Aktiengesellschaft to Report Q3, 2025 Results on Nov 10, 2025Biotest Aktiengesellschaft announced that they will report Q3, 2025 results on Nov 10, 2025お知らせ • Mar 07Martin Möller to Leave as Chief Financial Officer of Biotest AG on 15 March 2025The Board of Management of Biotest AG announced that Chief Financial Officer Martin Möller will terminate his position as CFO as planned at the end of his contract expires on 15 March 2025. The Supervisory Board has already initiated the search for a suitable successor and aims to fill the position in the near future. Martin Möller will continue to support Biotest AG in an advisory capacity beyond the end of his contract.お知らせ • Jan 09Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA)Biotest AG announced that the Biologics License Application (BLA) for Biotest’s Fibrinogen has been submitted to the US Food and Drug Administration. Fibrinogen is the second product developed and manufactured by Biotest in Dreieich, Germany, for which a BLA has been submitted to the FDA. The new application covers both supplementation in patients with acquired fibrinogen deficiency and treatment and prophylaxis of acute bleeding episodes in all patients with congenital fibrinogen deficiency. The application is now under evaluation by the FDA, with a decision anticipated by the end of 2025. This submission follows Biotest’s earlier application for marketing authorization in selected European markets filed in October 2024. In many regions of the world, the use of cryoprecipitate or fresh frozen plasma as a fibrinogen substitute is the standard of care for the management of major surgical bleeding. However, these treatments contain not only fibrinogen, but also additional proteins and components that may exhibit undesired effects for the patient. In addition, they are not subject to the same rigorous pathogen safety protocols as Fibrinogen. Fibrinogen also offers the significant advantages of being readily available and allowing for faster administration, ensuring timely and targeted treatment.Reported Earnings • Nov 17Third quarter 2024 earnings releasedThird quarter 2024 results: €0.25 loss per share. Revenue: €150.7m (down 40% from 3Q 2023). Net loss: €9.30m (down 108% from profit in 3Q 2023). Revenue is forecast to grow 6.0% p.a. on average during the next 2 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.お知らせ • Nov 15Biotest Aktiengesellschaft to Report Fiscal Year 2024 Results on Mar 28, 2025Biotest Aktiengesellschaft announced that they will report fiscal year 2024 results on Mar 28, 2025Reported Earnings • Aug 07Second quarter 2024 earnings released: EPS: €0.24 (vs €0.075 loss in 2Q 2023)Second quarter 2024 results: EPS: €0.24 (up from €0.075 loss in 2Q 2023). Revenue: €156.8m (up 20% from 2Q 2023). Net income: €9.70m (up €15.3m from 2Q 2023). Profit margin: 6.2% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Revenue is expected to decline by 6.2% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Europe are expected to grow by 20%. Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.お知らせ • Jul 29Biotest Aktiengesellschaft to Report Q2, 2024 Results on Aug 06, 2024Biotest Aktiengesellschaft announced that they will report Q2, 2024 results on Aug 06, 2024お知らせ • Jun 18Biotest Receives FDA Approval for Innovative Yimmugo Immunoglobulin to Treat Primary ImmunodeficienciesGrifols announced that Biotest, a Grifols Group company, has received approval from the United States Food and Drug Administration (FDA) for Yimmugo®, an innovative intravenous immunoglobulin (Ig) therapeutic, to treat primary immunodeficiencies (PID). Yimmugo, developed by Biotest, adds to Grifols’ strong franchise of industry-leading intravenous and subcutaneous Ig treatments at a time of growing demand for plasma-derived medicines to treat immunodeficiencies, in which a part of the body’s immune system is missing or does not function properly, and other medical conditions. The first U.S.-approved medicine in Biotest’s portfolio, Yimmugo is produced using a state-of-the-art process at Biotest’s new FDA-certified “Next Level” production facility in Dreieich, Germany, which is already approved for production and marketing in Europe. The launch of Yimmugo in the U.S. in the second part of 2024 follows its successful introduction in Europe at the end of 2022 and is poised to add to Grifols' future revenue growth and profitability. Yimmugo is the first of a threesome of Biotest plasma proteins on the horizon destined for markets including the U.S. The other two, both in late-stage development, are a fibrinogen concentrate (FC) to treat acquired fibrinogen deficiency – it would be the first FC approved for this indication in the U.S. – and trimodulin, a polyvalent Ig to treat community-acquired pneumonia (CAP) or severe community-acquired pneumonia (sCAP). The strategic acquisition of Biotest and the integration of its specialized resources has significantly accelerated Grifols innovation, deepened its product pipeline and furthered its industry leadership. Yimmugo is a newly developed polyvalent immunoglobulin G preparation from human blood plasma for intravenous administration (IVIg). The sugar-free ready-to-use solution is approved in the US for substitution therapy in primary antibody deficiency syndromes. Yimmugo is the first approved product from the new Biotest Next Level production facility. The modern production process stands for the highest product quality and an extremely responsible use of resources. Important Safety Information: Thrombosis may occur with immune globulin intravenous (IGIV) products, including YIMMUGO. Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with the administration of IGIV products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. YIMMUGO does not contain sucrose. For patients at risk of thrombosis, renal dysfunction or renal failure, administer YIMMUGO at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.Reported Earnings • May 07First quarter 2024 earnings released: EPS: €0.74 (vs €0.53 loss in 1Q 2023)First quarter 2024 results: EPS: €0.74 (up from €0.53 loss in 1Q 2023). Revenue: €215.2m (up 84% from 1Q 2023). Net income: €29.5m (up €49.9m from 1Q 2023). Profit margin: 14% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. Revenue is expected to decline by 4.8% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Europe are expected to grow by 18%. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Upcoming Dividend • May 01Upcoming dividend of €0.08 per shareEligible shareholders must have bought the stock before 08 May 2024. Payment date: 13 May 2024. Trailing yield: 0.1%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (1.8%).New Risk • Mar 30New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 53% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.9x net interest cover). Earnings are forecast to decline by an average of 53% per year for the foreseeable future.Reported Earnings • Mar 30Full year 2023 earnings: Revenues exceed analyst expectationsFull year 2023 results: Revenue: €684.6m (up 33% from FY 2022). Net income: €127.0m (up €158.7m from FY 2022). Profit margin: 19% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 21%. Revenue is forecast to grow 2.0% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in Germany.お知らせ • Mar 29Biotest Aktiengesellschaft, Annual General Meeting, May 07, 2024Biotest Aktiengesellschaft, Annual General Meeting, May 07, 2024, at 10:30 Central European Standard Time. Location: Alte Oper Frankfurt, Mozart Saal, Opernplatz, Franfurt Am Main Germany Agenda: To consider the adopted annual financial statements of Biotest AG and the approved consolidated financial statements as at 31 December 2023; to consider the Resolution on the discharge of the members of the Management Board for the financial year 2023; to consider Resolution on the discharge of the members of the Supervisory Board for the financial year 2023; to consider the Election of the auditor for the financial year 2024; and to consider the other business matters.お知らせ • Jan 23+ 2 more updatesBiotest Aktiengesellschaft to Report First Half, 2024 Results on Jul 30, 2024Biotest Aktiengesellschaft announced that they will report first half, 2024 results on Jul 30, 2024お知らせ • Nov 03Biotest Aktiengesellschaft to Report Fiscal Year 2023 Results on Mar 28, 2024Biotest Aktiengesellschaft announced that they will report fiscal year 2023 results on Mar 28, 2024Reported Earnings • Nov 02Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: €252.8m (up 135% from 3Q 2022). Net income: €114.4m (up €128.7m from 3Q 2022). Profit margin: 45% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.お知らせ • Oct 07Biotest Aktiengesellschaft Raises Earnings Guidance for the Year 2023Biotest Aktiengesellschaft raised earnings guidance for the year 2023. Biotest AG had forecasted in April 2023 an EBIT that may possibly exceed EUR 100 million. Based on current information, the Executive Board expects EBIT for fiscal 2023 to be in the order of EUR 130 - 170 million. The Executive Board continues to aim for a mid-single-digit percentage increase in revenue for the 2023 financial year compared to 2022, excluding revenue from the technology transfer and licensing agreement.お知らせ • Oct 06Biotest AG Appoints Peter Janssen as Chairman of the Management Board, Effective from January 1, 2024Biotest AG at its meeting held on October 5, 2023 appointed Mr. Peter Janssen (57) as Chairman of the Management Board of Biotest AG with effect from 1 January 2024. He will take over the chairmanship of the Board of Management from Dr Michael Ramroth (62), who held this position for three and a half years and is retiring as planned for reasons of age. Peter Janssen has been a member of the Management Board of Biotest AG since 2022 and heads the Commercial and Industrial Operations divisions. Previously, he was Executive VP of Prothya Netherlands and CEO of Prothya Belgium. Mr. Janssen also worked for Pfizer for 14 years and for its animal health spin-off Zoetis for 5 years. Peter Janssen started his career as an assistant professor at the University of Leuven in Belgium, was a reserve officer in the Belgian Air Force and worked in the semiconductor division of the industrial gas company Air Products in Pennsylvania, USA. He holds a Master of Science (Dipl. Ing.) in Electromechanics, a Master in Business Administration and a Management Diploma from INSEAD in France. In addition to Peter Janssen as Chairman of the Management Board, the Management Board of Biotest AG will continue to include Ainhoa Mendizabal Zubiaga as CFO and Dr. Jörg Schüttrumpf as CSO.New Risk • Sep 27New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€146m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. This is currently the only risk that has been identified for the company.お知らせ • Sep 13Biotest Treats First Patient with Severe Community- Acquired Pneumonia in Phase III Trial with TrimodulinBiotest announced that the first patient with sCAP has been treated in the phase III ESsCAPE trial in an intensive care unit. This multinational phase III clinical trial is expected to enrol approximately 590 adult patients with severe Community Acquired Pneumonia (sCAP). The ESsCAPE trial will be conducted in up to 20 countries worldwide and patients will receive either trimodulin or placebo as add-on therapy to standard of care. Severe CAP is a life-threatening condition. Patients must be admitted to an intensive care unit (ICU) and often receive oxygen through invasive mechanical ventilation (IMV). These patients often develop additional critical illnesses such as sepsis, septic shock, and multiple organ dysfunction or failure. Despite existing treatment options, mortality in these patients remains high. The clinical concept of this prospective, double-blind, placebo-controlled phase III trial, was developed based on the promising results of the previous phase II clinical trial (CIGMA) in 160 sCAP patients requiring IMV. In the CIGMA trial a subgroup of patients with evidence of severe inflammation showed an encouraging reduction in the mortality rate when treated with trimodulin. Biotest's development product trimodulin is a globally unique, innovative polyvalent IgM, IgA, IgG antibody composition, purified from human plasma. In addition to clinical development for sCAP, trimodulin is also currently in development for the treatment of COVID-19. Biotest's development products trimodulin is an innovative polyvalent antibody composition, purified from human Plasma. In comparison to standard IgG preparations (IVIG), trimodulin contains relevant amounts of IgM and IgA in addition to IgG. Trimodulin is currently in clinical development for the treatment of patients with severe community-acquired pneumonia (sCAP) and for patients with moderate or severe COVID-19. Research so far has shown that trimodulin could intervene with a number of mechanisms involved in pathological processes that would otherwise lead to respiratory failure, sepsis, multi-organ failure and finally to death of the patient. Due to the large variety of polyvalent antibodies present in trimodulin, the impaired immune system is supported in various ways. The antibodies bind to various types of pathogens including viruses and bacteria as well as their toxins and support their clearance by the immune system. Particularly the IgM component in trimodulin can reduce dysregulated immune responses, preventing the immune system to attack host tissues, in this case, the lung. In this way, trimodulin may prevent progression of disease, including the need for invasive mechanical ventilation and other intensive care procedures, and finally death. Severe community acquired pneumonia (sCAP) is usually defined as pneumonia acquired outside the hospital that requires intensive medical care. mortality of sCAP patients admitted to the intensive care unit is high and has not improved much in recent years.お知らせ • Sep 08Biotest AG Announces US Food and Drug Administration Accepts Marketing Authorization Application for Immunoglobulin YimmugoBiotest AG announced that the Biologics License Application (BLA) for the polyspecific immunoglobulin preparation Yimmugo (IgG Next Generation) has been accepted for review by the U.S. Food and Drug Administration (FDA) after the 60-day validation phase. With this filing notification the marketing authorization application will enter the next phase, in which the application dossier will be subjected to an in-depth substantive review. The marketing authorization application covers the indication primary immunodeficiencies (PID). After receiving approval, Biotest plans to expand the indication to include chronic primary immune thrombocytopenia (ITP). The FDA's decision on the marketing authorization application of Yimmugo is expected on June 29, 2024. Biotest's new immunoglobulin is manufactured in an innovative production process and is the main product of the new Biotest Next Level production facility. The new production facility, which uses technologies, represents Biotest's increased commitment to the global immunoglobulin market.Reported Earnings • Aug 13Second quarter 2023 earnings released: EPS: €0.55 (vs €0.39 loss in 2Q 2022)Second quarter 2023 results: EPS: €0.55 (up from €0.39 loss in 2Q 2022). Revenue: €158.0m (up 15% from 2Q 2022). Net income: €22.2m (up €37.2m from 2Q 2022). Profit margin: 14% (up from net loss in 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.Reported Earnings • May 10First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: €117.2m (up 1.1% from 1Q 2022). Net loss: €20.4m (loss widened 316% from 1Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany.Reported Earnings • Mar 24Full year 2022 earnings: Revenues miss analyst expectationsFull year 2022 results: Revenue: €516.1m (flat on FY 2021). Net loss: €31.7m (loss narrowed 50% from FY 2021). Revenue missed analyst estimates by 2.2%. Revenue is forecast to grow 9.5% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings.Buying Opportunity • Mar 13Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 5.0%. The fair value is estimated to be €40.14, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.5% over the last 3 years. Earnings per share has declined by 56%. Revenue is forecast to grow by 21% in 2 years. Earnings is forecast to grow by 86% in the next 2 years.お知らせ • Feb 11Biotest AG Appoints Ainhoa Mendizabal as CFO, with Effect from 15 February, 2023Biotest AG appointed Ms. Ainhoa Mendizabal (50) to the company's Management Board as Chief Financial Officer (CFO) with effect from 15 February 2023. When Dr. Michael Ramroth was appointed Chief Executive Officer (CEO) on 1 May 2019, he initially continued to perform the duties of Chief Financial Officer in addition to his other duties. In view of the constantly growing reporting requirements, the company has now filled the position of Chief Financial Officer with Ms Mendizabal. As 'Chief Financial Officer', Ms. Mendizabal will be responsible within the Biotest Group for the areas of finance, including the treasury and tax departments, controlling, investor relations and insurance. Ms Mendizabal has worked for several years in an international consulting firm in the area of CFO Services and Enterprise Applications. From there she moved to Talecris Biotherapeutics GmbH before Talecris was acquired by Grifols S.A. Since then, Ms Mendizabal has held various executive and managerial roles in the Grifols Group in Germany and in Europe. Ms. Mendizabal holds a dual Master of Business Administration (Business Administration) in Spain and in Germany.お知らせ • Dec 20+ 2 more updatesBiotest Aktiengesellschaft to Report Fiscal Year 2022 Results on Mar 23, 2023Biotest Aktiengesellschaft announced that they will report fiscal year 2022 results at 12:00 PM, Central European Standard Time on Mar 23, 2023Reported Earnings • Nov 16Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: €107.7m (down 5.2% from 3Q 2021). Net loss: €14.3m (loss widened 42% from 3Q 2021). Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in Germany.Breakeven Date Change • Sep 15No longer forecast to breakevenThe 2 analysts covering Biotest no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €9.06m in 2023. New consensus forecast suggests the company will make a loss of €3.00m in 2024.Reported Earnings • Aug 14Second quarter 2022 earnings released: €0.39 loss per share (vs €0.11 loss in 2Q 2021)Second quarter 2022 results: €0.39 loss per share (down from €0.11 loss in 2Q 2021). Revenue: €137.2m (flat on 2Q 2021). Net loss: €15.0m (loss widened 266% from 2Q 2021). Over the next year, revenue is forecast to grow 11%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance.Reported Earnings • May 06First quarter 2022 earnings: Revenues in line with analyst expectationsFirst quarter 2022 results: Revenue: €115.9m (down 3.4% from 1Q 2021). Net loss: €4.90m (loss narrowed 65% from 1Q 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 2.5%, compared to a 28% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 89 percentage points per year, which is a significant difference in performance.Upcoming Dividend • Apr 29Upcoming dividend of €0.04 per shareEligible shareholders must have bought the stock before 06 May 2022. Payment date: 10 May 2022. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.1%. Lower than top quartile of German dividend payers (4.0%). Lower than average of industry peers (1.4%).Major Estimate Revision • Apr 04Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate increased from €0.06 to €0.08. Revenue forecast steady at €559.5m. Net income forecast to grow 60% next year vs 24% growth forecast for Biotechs industry in Germany. Consensus price target of €36.58 unchanged from last update. Share price was steady at €34.70 over the past week.Major Estimate Revision • Dec 11Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 expected loss increased from -€0.53 to -€1.06 per share. Revenue forecast unchanged at €511.5m. Biotechs industry in Germany expected to see average net income growth of 3.4% next year. Consensus price target broadly unchanged at €39.13. Share price fell 2.8% to €38.10 over the past week.Price Target Changed • Nov 13Price target increased to €38.93Up from €36.23, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of €39.00. The company is forecast to post a net loss per share of €0.54 next year compared to a net loss per share of €0.80 last year.Reported Earnings • Nov 12Third quarter 2021 earnings releasedThe company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: €113.6m (up 6.4% from 3Q 2020). Net loss: €10.1m (loss narrowed 33% from 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 107 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 13Second quarter 2021 earnings released: €0.11 loss per share (vs €0.16 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses and improved control over expenses, although revenues were flat. Second quarter 2021 results: Revenue: €137.8m (flat on 2Q 2020). Net loss: €4.10m (loss narrowed 29% from 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 101 percentage points per year, which is a significant difference in performance.Reported Earnings • May 12First quarter 2021 earnings released: €0.37 loss per share (vs €0.28 loss in 1Q 2020)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: €120.0m (up 23% from 1Q 2020). Net loss: €14.1m (loss widened 31% from 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 99 percentage points per year, which is a significant difference in performance.Upcoming Dividend • May 05Upcoming dividend of €0.04 per shareEligible shareholders must have bought the stock before 12 May 2021. Payment date: 17 May 2021. Trailing yield: 0.1%. Lower than top quartile of German dividend payers (3.1%). Lower than average of industry peers (0.5%).Reported Earnings • Apr 04Full year 2020 earnings released: €0.80 loss per share (vs €0.13 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €484.2m (up 16% from FY 2019). Net loss: €31.8m (loss widened €26.7m from FY 2019). Products in clinical trials Phase I: 1 Phase II: 1 Phase III: 5 Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.Major Estimate Revision • Apr 02Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from €497.9m to €508.0m. Forecast EPS reduced from -€0.52 to -€0.60 per share. Biotechs industry in Germany expected to see average net income growth of 7.3% next year. Consensus price target up from €31.20 to €35.60. Share price was steady at €29.90 over the past week.Is New 90 Day High Low • Feb 12New 90-day high: €28.80The company is up 10.0% from its price of €26.10 on 13 November 2020. The German market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 11% over the same period.Is New 90 Day High Low • Jan 14New 90-day high: €28.50The company is up 4.0% from its price of €27.40 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Biotechs industry, which is also up 4.0% over the same period.Reported Earnings • Nov 13Third quarter 2020 earnings released: €0.39 loss per shareThe company reported a soft third quarter result with increased losses and weaker control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: €106.8m (up 7.0% from 3Q 2019). Net loss: €15.1m (loss widened 208% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.Major Estimate Revision • Sep 25Analysts update estimatesThe company's losses in 2020 are expected to worsen with analysts lowering their consensus EPS forecasts from -€0.64 to -€0.72. Revenue estimate was approximately flat at €461.0m. The Biotechs industry in Germany is expected to see an average net income growth of 9.9% next year. The consensus price target increased from €24.10 to €31.20. Share price is down by 2.0% to €24.80 over the past week.株主還元BIO3DE BiotechsDE 市場7D0%1.9%2.0%1Y4.8%-11.3%-0.1%株主還元を見る業界別リターン: BIO3過去 1 年間で-11.3 % の収益を上げたGerman Biotechs業界を上回りました。リターン対市場: BIO3は、過去 1 年間で-0.1 % のリターンを上げたGerman市場を下回りました。価格変動Is BIO3's price volatile compared to industry and market?BIO3 volatilityBIO3 Average Weekly Movementn/aBiotechs Industry Average Movement8.9%Market Average Movement6.2%10% most volatile stocks in DE Market13.3%10% least volatile stocks in DE Market2.7%安定した株価: BIO3の株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のBIO3のボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト19462,495Jorg Schuttrumpfwww.biotest.comバイオテスト・アクチェンゲゼルシャフトは、ドイツ国内および国際的に生物学的およびバイオテクノロジー医薬品の開発、製造、販売を行っている。3つのセグメントで事業を展開：欧州連合、その他の地域、無国籍。同社は主に臨床免疫学、血液学、集中治療医学の治療分野に特化している。同社の製品には、血友病A急性期治療および予防のためのHaemoctinおよびVihuma、血友病B急性期治療および予防のためのHaemonineがある。また、サイトメガロウイルス感染症治療薬Cytotect CP biotest、新生児B型肝炎免疫予防薬Fovepta、B型肝炎再感染予防薬Hepatect、一次免疫不全症候群・二次抗体不全症候群および自己免疫疾患（神経を含む）治療薬IntratectおよびYimmugo、水痘帯状疱疹ウイルス感染症治療薬Varitect、B型肝炎免疫グロブリン治療薬Zutectraを提供している。さらに、循環血液量の回復と維持のためのアルビオミンとビセコ、凝固因子欠乏症のためのコファクト、先天性フィブリノゲン欠乏症の治療のためのフィブリノゲン、市中肺炎とCOVID-19のためのトリモジュリン、細菌感染症の治療のためのペンタグロビンを提供している。同社は以前Biotest Serum-Institut GmbHとして知られ、1986年にBiotest Aktiengesellschaftに社名を変更した。同社は1946年に設立され、ドイツのドライヒに本社を置く。Biotest AktiengesellschaftはGrifols Biotest Holdings GmbHの子会社である。もっと見るBiotest Aktiengesellschaft 基礎のまとめBiotest の収益と売上を時価総額と比較するとどうか。BIO3 基礎統計学時価総額€1.40b収益（TTM）-€24.50m売上高(TTM)€635.20m1.8xP/Sレシオ-45.9xPER（株価収益率BIO3 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計BIO3 損益計算書（TTM）収益€635.20m売上原価€487.90m売上総利益€147.30mその他の費用€171.80m収益-€24.50m直近の収益報告Mar 31, 2025次回決算日Nov 10, 2025一株当たり利益（EPS）-0.62グロス・マージン23.19%純利益率-3.86%有利子負債／自己資本比率131.2%BIO3 の長期的なパフォーマンスは？過去の実績と比較を見る配当金0.1%現在の配当利回り-6%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/09/03 09:40終値2025/06/06 00:00収益2025/03/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Biotest GmbH & Co. KGaA 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Torben TeichlerHauck Aufhäuser Investment BankingJan KeppelerHSBCKlaus SchloteSolventis Wertpapierhandelsbank GmbH
お知らせ • May 23Biotest Aktiengesellschaft announces Annual dividend, payable on July 07, 2025Biotest Aktiengesellschaft announced Annual dividend of EUR 0.0400 per share payable on July 07, 2025, ex-date on July 03, 2025 and record date on July 04, 2025.
お知らせ • May 22Biotest Aktiengesellschaft, Annual General Meeting, Jul 02, 2025Biotest Aktiengesellschaft, Annual General Meeting, Jul 02, 2025, at 10:30 W. Europe Standard Time.
Reported Earnings • May 14First quarter 2025 earnings released: €0.55 loss per share (vs €0.74 profit in 1Q 2024)First quarter 2025 results: €0.55 loss per share (down from €0.74 profit in 1Q 2024). Revenue: €124.2m (down 42% from 1Q 2024). Net loss: €21.4m (down 173% from profit in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
お知らせ • Apr 02Grifols Biotest Holdings GmbH, proposed to acquire remaining 28.31% stake in Biotest Aktiengesellschaft (XTRA:BIO3) from shareholders for approximately €340 million.Grifols Biotest Holdings GmbH, proposed to acquire remaining 28.31% stake in Biotest Aktiengesellschaft (XTRA:BIO3) from shareholders for approximately €340 million on March 31, 2025. The Management Board and the Supervisory Board will carefully review the offer document for the public delisting acquisition offer and issue a joint reasoned statement in accordance with Section 27 of the German Securities Acquisition and Takeover Act. The delisting agreement contains provisions that Grifols, S.A. intends to support Biotest AG in an economically reasonable manner. After the revocation of the stock exchange admission becomes effective, the shares of Biotest AG will no longer be admitted to trading on a domestic regulated market or a comparable market abroad. According to the provisions of the delisting agreement, Grifols Biotest Holdings GmbH, a 100% subsidiary of Grifols, S.A., will make an unconditional public delisting acquisition offer to the shareholders of Biotest AG to acquire all ordinary and preference shares of Biotest AG that are not already held by Grifols Biotest Holdings GmbH, in exchange for a cash consideration of €43.00 per Biotest ordinary share and €30.00 per Biotest preference share, subject to adjustments due to legal provisions. The terms and conditions of the delisting offer will be communicated in the offer document ("Offer Document") to be prepared by Grifols and to be examined by the German federal financial supervisory. Banco Santander, S.A. acted as a financial advisor to Biotest Aktiengesellschaft.
Reported Earnings • Apr 01Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: EPS: €0.66 (down from €3.21 in FY 2023). Revenue: €726.2m (up 6.1% from FY 2023). Net income: €26.4m (down 79% from FY 2023). Profit margin: 3.6% (down from 19% in FY 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
お知らせ • Mar 18+ 1 more updateBiotest Aktiengesellschaft to Report Q3, 2025 Results on Nov 10, 2025Biotest Aktiengesellschaft announced that they will report Q3, 2025 results on Nov 10, 2025
お知らせ • May 23Biotest Aktiengesellschaft announces Annual dividend, payable on July 07, 2025Biotest Aktiengesellschaft announced Annual dividend of EUR 0.0400 per share payable on July 07, 2025, ex-date on July 03, 2025 and record date on July 04, 2025.
お知らせ • May 22Biotest Aktiengesellschaft, Annual General Meeting, Jul 02, 2025Biotest Aktiengesellschaft, Annual General Meeting, Jul 02, 2025, at 10:30 W. Europe Standard Time.
Reported Earnings • May 14First quarter 2025 earnings released: €0.55 loss per share (vs €0.74 profit in 1Q 2024)First quarter 2025 results: €0.55 loss per share (down from €0.74 profit in 1Q 2024). Revenue: €124.2m (down 42% from 1Q 2024). Net loss: €21.4m (down 173% from profit in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
お知らせ • Apr 02Grifols Biotest Holdings GmbH, proposed to acquire remaining 28.31% stake in Biotest Aktiengesellschaft (XTRA:BIO3) from shareholders for approximately €340 million.Grifols Biotest Holdings GmbH, proposed to acquire remaining 28.31% stake in Biotest Aktiengesellschaft (XTRA:BIO3) from shareholders for approximately €340 million on March 31, 2025. The Management Board and the Supervisory Board will carefully review the offer document for the public delisting acquisition offer and issue a joint reasoned statement in accordance with Section 27 of the German Securities Acquisition and Takeover Act. The delisting agreement contains provisions that Grifols, S.A. intends to support Biotest AG in an economically reasonable manner. After the revocation of the stock exchange admission becomes effective, the shares of Biotest AG will no longer be admitted to trading on a domestic regulated market or a comparable market abroad. According to the provisions of the delisting agreement, Grifols Biotest Holdings GmbH, a 100% subsidiary of Grifols, S.A., will make an unconditional public delisting acquisition offer to the shareholders of Biotest AG to acquire all ordinary and preference shares of Biotest AG that are not already held by Grifols Biotest Holdings GmbH, in exchange for a cash consideration of €43.00 per Biotest ordinary share and €30.00 per Biotest preference share, subject to adjustments due to legal provisions. The terms and conditions of the delisting offer will be communicated in the offer document ("Offer Document") to be prepared by Grifols and to be examined by the German federal financial supervisory. Banco Santander, S.A. acted as a financial advisor to Biotest Aktiengesellschaft.
Reported Earnings • Apr 01Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: EPS: €0.66 (down from €3.21 in FY 2023). Revenue: €726.2m (up 6.1% from FY 2023). Net income: €26.4m (down 79% from FY 2023). Profit margin: 3.6% (down from 19% in FY 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
お知らせ • Mar 18+ 1 more updateBiotest Aktiengesellschaft to Report Q3, 2025 Results on Nov 10, 2025Biotest Aktiengesellschaft announced that they will report Q3, 2025 results on Nov 10, 2025
お知らせ • Mar 07Martin Möller to Leave as Chief Financial Officer of Biotest AG on 15 March 2025The Board of Management of Biotest AG announced that Chief Financial Officer Martin Möller will terminate his position as CFO as planned at the end of his contract expires on 15 March 2025. The Supervisory Board has already initiated the search for a suitable successor and aims to fill the position in the near future. Martin Möller will continue to support Biotest AG in an advisory capacity beyond the end of his contract.
お知らせ • Jan 09Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA)Biotest AG announced that the Biologics License Application (BLA) for Biotest’s Fibrinogen has been submitted to the US Food and Drug Administration. Fibrinogen is the second product developed and manufactured by Biotest in Dreieich, Germany, for which a BLA has been submitted to the FDA. The new application covers both supplementation in patients with acquired fibrinogen deficiency and treatment and prophylaxis of acute bleeding episodes in all patients with congenital fibrinogen deficiency. The application is now under evaluation by the FDA, with a decision anticipated by the end of 2025. This submission follows Biotest’s earlier application for marketing authorization in selected European markets filed in October 2024. In many regions of the world, the use of cryoprecipitate or fresh frozen plasma as a fibrinogen substitute is the standard of care for the management of major surgical bleeding. However, these treatments contain not only fibrinogen, but also additional proteins and components that may exhibit undesired effects for the patient. In addition, they are not subject to the same rigorous pathogen safety protocols as Fibrinogen. Fibrinogen also offers the significant advantages of being readily available and allowing for faster administration, ensuring timely and targeted treatment.
Reported Earnings • Nov 17Third quarter 2024 earnings releasedThird quarter 2024 results: €0.25 loss per share. Revenue: €150.7m (down 40% from 3Q 2023). Net loss: €9.30m (down 108% from profit in 3Q 2023). Revenue is forecast to grow 6.0% p.a. on average during the next 2 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
お知らせ • Nov 15Biotest Aktiengesellschaft to Report Fiscal Year 2024 Results on Mar 28, 2025Biotest Aktiengesellschaft announced that they will report fiscal year 2024 results on Mar 28, 2025
Reported Earnings • Aug 07Second quarter 2024 earnings released: EPS: €0.24 (vs €0.075 loss in 2Q 2023)Second quarter 2024 results: EPS: €0.24 (up from €0.075 loss in 2Q 2023). Revenue: €156.8m (up 20% from 2Q 2023). Net income: €9.70m (up €15.3m from 2Q 2023). Profit margin: 6.2% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Revenue is expected to decline by 6.2% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Europe are expected to grow by 20%. Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
お知らせ • Jul 29Biotest Aktiengesellschaft to Report Q2, 2024 Results on Aug 06, 2024Biotest Aktiengesellschaft announced that they will report Q2, 2024 results on Aug 06, 2024
お知らせ • Jun 18Biotest Receives FDA Approval for Innovative Yimmugo Immunoglobulin to Treat Primary ImmunodeficienciesGrifols announced that Biotest, a Grifols Group company, has received approval from the United States Food and Drug Administration (FDA) for Yimmugo®, an innovative intravenous immunoglobulin (Ig) therapeutic, to treat primary immunodeficiencies (PID). Yimmugo, developed by Biotest, adds to Grifols’ strong franchise of industry-leading intravenous and subcutaneous Ig treatments at a time of growing demand for plasma-derived medicines to treat immunodeficiencies, in which a part of the body’s immune system is missing or does not function properly, and other medical conditions. The first U.S.-approved medicine in Biotest’s portfolio, Yimmugo is produced using a state-of-the-art process at Biotest’s new FDA-certified “Next Level” production facility in Dreieich, Germany, which is already approved for production and marketing in Europe. The launch of Yimmugo in the U.S. in the second part of 2024 follows its successful introduction in Europe at the end of 2022 and is poised to add to Grifols' future revenue growth and profitability. Yimmugo is the first of a threesome of Biotest plasma proteins on the horizon destined for markets including the U.S. The other two, both in late-stage development, are a fibrinogen concentrate (FC) to treat acquired fibrinogen deficiency – it would be the first FC approved for this indication in the U.S. – and trimodulin, a polyvalent Ig to treat community-acquired pneumonia (CAP) or severe community-acquired pneumonia (sCAP). The strategic acquisition of Biotest and the integration of its specialized resources has significantly accelerated Grifols innovation, deepened its product pipeline and furthered its industry leadership. Yimmugo is a newly developed polyvalent immunoglobulin G preparation from human blood plasma for intravenous administration (IVIg). The sugar-free ready-to-use solution is approved in the US for substitution therapy in primary antibody deficiency syndromes. Yimmugo is the first approved product from the new Biotest Next Level production facility. The modern production process stands for the highest product quality and an extremely responsible use of resources. Important Safety Information: Thrombosis may occur with immune globulin intravenous (IGIV) products, including YIMMUGO. Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with the administration of IGIV products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. YIMMUGO does not contain sucrose. For patients at risk of thrombosis, renal dysfunction or renal failure, administer YIMMUGO at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
Reported Earnings • May 07First quarter 2024 earnings released: EPS: €0.74 (vs €0.53 loss in 1Q 2023)First quarter 2024 results: EPS: €0.74 (up from €0.53 loss in 1Q 2023). Revenue: €215.2m (up 84% from 1Q 2023). Net income: €29.5m (up €49.9m from 1Q 2023). Profit margin: 14% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. Revenue is expected to decline by 4.8% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Europe are expected to grow by 18%. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Upcoming Dividend • May 01Upcoming dividend of €0.08 per shareEligible shareholders must have bought the stock before 08 May 2024. Payment date: 13 May 2024. Trailing yield: 0.1%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (1.8%).
New Risk • Mar 30New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 53% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.9x net interest cover). Earnings are forecast to decline by an average of 53% per year for the foreseeable future.
Reported Earnings • Mar 30Full year 2023 earnings: Revenues exceed analyst expectationsFull year 2023 results: Revenue: €684.6m (up 33% from FY 2022). Net income: €127.0m (up €158.7m from FY 2022). Profit margin: 19% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 21%. Revenue is forecast to grow 2.0% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in Germany.
お知らせ • Mar 29Biotest Aktiengesellschaft, Annual General Meeting, May 07, 2024Biotest Aktiengesellschaft, Annual General Meeting, May 07, 2024, at 10:30 Central European Standard Time. Location: Alte Oper Frankfurt, Mozart Saal, Opernplatz, Franfurt Am Main Germany Agenda: To consider the adopted annual financial statements of Biotest AG and the approved consolidated financial statements as at 31 December 2023; to consider the Resolution on the discharge of the members of the Management Board for the financial year 2023; to consider Resolution on the discharge of the members of the Supervisory Board for the financial year 2023; to consider the Election of the auditor for the financial year 2024; and to consider the other business matters.
お知らせ • Jan 23+ 2 more updatesBiotest Aktiengesellschaft to Report First Half, 2024 Results on Jul 30, 2024Biotest Aktiengesellschaft announced that they will report first half, 2024 results on Jul 30, 2024
お知らせ • Nov 03Biotest Aktiengesellschaft to Report Fiscal Year 2023 Results on Mar 28, 2024Biotest Aktiengesellschaft announced that they will report fiscal year 2023 results on Mar 28, 2024
Reported Earnings • Nov 02Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: €252.8m (up 135% from 3Q 2022). Net income: €114.4m (up €128.7m from 3Q 2022). Profit margin: 45% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
お知らせ • Oct 07Biotest Aktiengesellschaft Raises Earnings Guidance for the Year 2023Biotest Aktiengesellschaft raised earnings guidance for the year 2023. Biotest AG had forecasted in April 2023 an EBIT that may possibly exceed EUR 100 million. Based on current information, the Executive Board expects EBIT for fiscal 2023 to be in the order of EUR 130 - 170 million. The Executive Board continues to aim for a mid-single-digit percentage increase in revenue for the 2023 financial year compared to 2022, excluding revenue from the technology transfer and licensing agreement.
お知らせ • Oct 06Biotest AG Appoints Peter Janssen as Chairman of the Management Board, Effective from January 1, 2024Biotest AG at its meeting held on October 5, 2023 appointed Mr. Peter Janssen (57) as Chairman of the Management Board of Biotest AG with effect from 1 January 2024. He will take over the chairmanship of the Board of Management from Dr Michael Ramroth (62), who held this position for three and a half years and is retiring as planned for reasons of age. Peter Janssen has been a member of the Management Board of Biotest AG since 2022 and heads the Commercial and Industrial Operations divisions. Previously, he was Executive VP of Prothya Netherlands and CEO of Prothya Belgium. Mr. Janssen also worked for Pfizer for 14 years and for its animal health spin-off Zoetis for 5 years. Peter Janssen started his career as an assistant professor at the University of Leuven in Belgium, was a reserve officer in the Belgian Air Force and worked in the semiconductor division of the industrial gas company Air Products in Pennsylvania, USA. He holds a Master of Science (Dipl. Ing.) in Electromechanics, a Master in Business Administration and a Management Diploma from INSEAD in France. In addition to Peter Janssen as Chairman of the Management Board, the Management Board of Biotest AG will continue to include Ainhoa Mendizabal Zubiaga as CFO and Dr. Jörg Schüttrumpf as CSO.
New Risk • Sep 27New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€146m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. This is currently the only risk that has been identified for the company.
お知らせ • Sep 13Biotest Treats First Patient with Severe Community- Acquired Pneumonia in Phase III Trial with TrimodulinBiotest announced that the first patient with sCAP has been treated in the phase III ESsCAPE trial in an intensive care unit. This multinational phase III clinical trial is expected to enrol approximately 590 adult patients with severe Community Acquired Pneumonia (sCAP). The ESsCAPE trial will be conducted in up to 20 countries worldwide and patients will receive either trimodulin or placebo as add-on therapy to standard of care. Severe CAP is a life-threatening condition. Patients must be admitted to an intensive care unit (ICU) and often receive oxygen through invasive mechanical ventilation (IMV). These patients often develop additional critical illnesses such as sepsis, septic shock, and multiple organ dysfunction or failure. Despite existing treatment options, mortality in these patients remains high. The clinical concept of this prospective, double-blind, placebo-controlled phase III trial, was developed based on the promising results of the previous phase II clinical trial (CIGMA) in 160 sCAP patients requiring IMV. In the CIGMA trial a subgroup of patients with evidence of severe inflammation showed an encouraging reduction in the mortality rate when treated with trimodulin. Biotest's development product trimodulin is a globally unique, innovative polyvalent IgM, IgA, IgG antibody composition, purified from human plasma. In addition to clinical development for sCAP, trimodulin is also currently in development for the treatment of COVID-19. Biotest's development products trimodulin is an innovative polyvalent antibody composition, purified from human Plasma. In comparison to standard IgG preparations (IVIG), trimodulin contains relevant amounts of IgM and IgA in addition to IgG. Trimodulin is currently in clinical development for the treatment of patients with severe community-acquired pneumonia (sCAP) and for patients with moderate or severe COVID-19. Research so far has shown that trimodulin could intervene with a number of mechanisms involved in pathological processes that would otherwise lead to respiratory failure, sepsis, multi-organ failure and finally to death of the patient. Due to the large variety of polyvalent antibodies present in trimodulin, the impaired immune system is supported in various ways. The antibodies bind to various types of pathogens including viruses and bacteria as well as their toxins and support their clearance by the immune system. Particularly the IgM component in trimodulin can reduce dysregulated immune responses, preventing the immune system to attack host tissues, in this case, the lung. In this way, trimodulin may prevent progression of disease, including the need for invasive mechanical ventilation and other intensive care procedures, and finally death. Severe community acquired pneumonia (sCAP) is usually defined as pneumonia acquired outside the hospital that requires intensive medical care. mortality of sCAP patients admitted to the intensive care unit is high and has not improved much in recent years.
お知らせ • Sep 08Biotest AG Announces US Food and Drug Administration Accepts Marketing Authorization Application for Immunoglobulin YimmugoBiotest AG announced that the Biologics License Application (BLA) for the polyspecific immunoglobulin preparation Yimmugo (IgG Next Generation) has been accepted for review by the U.S. Food and Drug Administration (FDA) after the 60-day validation phase. With this filing notification the marketing authorization application will enter the next phase, in which the application dossier will be subjected to an in-depth substantive review. The marketing authorization application covers the indication primary immunodeficiencies (PID). After receiving approval, Biotest plans to expand the indication to include chronic primary immune thrombocytopenia (ITP). The FDA's decision on the marketing authorization application of Yimmugo is expected on June 29, 2024. Biotest's new immunoglobulin is manufactured in an innovative production process and is the main product of the new Biotest Next Level production facility. The new production facility, which uses technologies, represents Biotest's increased commitment to the global immunoglobulin market.
Reported Earnings • Aug 13Second quarter 2023 earnings released: EPS: €0.55 (vs €0.39 loss in 2Q 2022)Second quarter 2023 results: EPS: €0.55 (up from €0.39 loss in 2Q 2022). Revenue: €158.0m (up 15% from 2Q 2022). Net income: €22.2m (up €37.2m from 2Q 2022). Profit margin: 14% (up from net loss in 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
Reported Earnings • May 10First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: €117.2m (up 1.1% from 1Q 2022). Net loss: €20.4m (loss widened 316% from 1Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany.
Reported Earnings • Mar 24Full year 2022 earnings: Revenues miss analyst expectationsFull year 2022 results: Revenue: €516.1m (flat on FY 2021). Net loss: €31.7m (loss narrowed 50% from FY 2021). Revenue missed analyst estimates by 2.2%. Revenue is forecast to grow 9.5% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings.
Buying Opportunity • Mar 13Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 5.0%. The fair value is estimated to be €40.14, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.5% over the last 3 years. Earnings per share has declined by 56%. Revenue is forecast to grow by 21% in 2 years. Earnings is forecast to grow by 86% in the next 2 years.
お知らせ • Feb 11Biotest AG Appoints Ainhoa Mendizabal as CFO, with Effect from 15 February, 2023Biotest AG appointed Ms. Ainhoa Mendizabal (50) to the company's Management Board as Chief Financial Officer (CFO) with effect from 15 February 2023. When Dr. Michael Ramroth was appointed Chief Executive Officer (CEO) on 1 May 2019, he initially continued to perform the duties of Chief Financial Officer in addition to his other duties. In view of the constantly growing reporting requirements, the company has now filled the position of Chief Financial Officer with Ms Mendizabal. As 'Chief Financial Officer', Ms. Mendizabal will be responsible within the Biotest Group for the areas of finance, including the treasury and tax departments, controlling, investor relations and insurance. Ms Mendizabal has worked for several years in an international consulting firm in the area of CFO Services and Enterprise Applications. From there she moved to Talecris Biotherapeutics GmbH before Talecris was acquired by Grifols S.A. Since then, Ms Mendizabal has held various executive and managerial roles in the Grifols Group in Germany and in Europe. Ms. Mendizabal holds a dual Master of Business Administration (Business Administration) in Spain and in Germany.
お知らせ • Dec 20+ 2 more updatesBiotest Aktiengesellschaft to Report Fiscal Year 2022 Results on Mar 23, 2023Biotest Aktiengesellschaft announced that they will report fiscal year 2022 results at 12:00 PM, Central European Standard Time on Mar 23, 2023
Reported Earnings • Nov 16Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: €107.7m (down 5.2% from 3Q 2021). Net loss: €14.3m (loss widened 42% from 3Q 2021). Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in Germany.
Breakeven Date Change • Sep 15No longer forecast to breakevenThe 2 analysts covering Biotest no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €9.06m in 2023. New consensus forecast suggests the company will make a loss of €3.00m in 2024.
Reported Earnings • Aug 14Second quarter 2022 earnings released: €0.39 loss per share (vs €0.11 loss in 2Q 2021)Second quarter 2022 results: €0.39 loss per share (down from €0.11 loss in 2Q 2021). Revenue: €137.2m (flat on 2Q 2021). Net loss: €15.0m (loss widened 266% from 2Q 2021). Over the next year, revenue is forecast to grow 11%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance.
Reported Earnings • May 06First quarter 2022 earnings: Revenues in line with analyst expectationsFirst quarter 2022 results: Revenue: €115.9m (down 3.4% from 1Q 2021). Net loss: €4.90m (loss narrowed 65% from 1Q 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 2.5%, compared to a 28% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 89 percentage points per year, which is a significant difference in performance.
Upcoming Dividend • Apr 29Upcoming dividend of €0.04 per shareEligible shareholders must have bought the stock before 06 May 2022. Payment date: 10 May 2022. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.1%. Lower than top quartile of German dividend payers (4.0%). Lower than average of industry peers (1.4%).
Major Estimate Revision • Apr 04Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate increased from €0.06 to €0.08. Revenue forecast steady at €559.5m. Net income forecast to grow 60% next year vs 24% growth forecast for Biotechs industry in Germany. Consensus price target of €36.58 unchanged from last update. Share price was steady at €34.70 over the past week.
Major Estimate Revision • Dec 11Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 expected loss increased from -€0.53 to -€1.06 per share. Revenue forecast unchanged at €511.5m. Biotechs industry in Germany expected to see average net income growth of 3.4% next year. Consensus price target broadly unchanged at €39.13. Share price fell 2.8% to €38.10 over the past week.
Price Target Changed • Nov 13Price target increased to €38.93Up from €36.23, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of €39.00. The company is forecast to post a net loss per share of €0.54 next year compared to a net loss per share of €0.80 last year.
Reported Earnings • Nov 12Third quarter 2021 earnings releasedThe company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: €113.6m (up 6.4% from 3Q 2020). Net loss: €10.1m (loss narrowed 33% from 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 107 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 13Second quarter 2021 earnings released: €0.11 loss per share (vs €0.16 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses and improved control over expenses, although revenues were flat. Second quarter 2021 results: Revenue: €137.8m (flat on 2Q 2020). Net loss: €4.10m (loss narrowed 29% from 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 101 percentage points per year, which is a significant difference in performance.
Reported Earnings • May 12First quarter 2021 earnings released: €0.37 loss per share (vs €0.28 loss in 1Q 2020)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: €120.0m (up 23% from 1Q 2020). Net loss: €14.1m (loss widened 31% from 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 99 percentage points per year, which is a significant difference in performance.
Upcoming Dividend • May 05Upcoming dividend of €0.04 per shareEligible shareholders must have bought the stock before 12 May 2021. Payment date: 17 May 2021. Trailing yield: 0.1%. Lower than top quartile of German dividend payers (3.1%). Lower than average of industry peers (0.5%).
Reported Earnings • Apr 04Full year 2020 earnings released: €0.80 loss per share (vs €0.13 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €484.2m (up 16% from FY 2019). Net loss: €31.8m (loss widened €26.7m from FY 2019). Products in clinical trials Phase I: 1 Phase II: 1 Phase III: 5 Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.
Major Estimate Revision • Apr 02Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from €497.9m to €508.0m. Forecast EPS reduced from -€0.52 to -€0.60 per share. Biotechs industry in Germany expected to see average net income growth of 7.3% next year. Consensus price target up from €31.20 to €35.60. Share price was steady at €29.90 over the past week.
Is New 90 Day High Low • Feb 12New 90-day high: €28.80The company is up 10.0% from its price of €26.10 on 13 November 2020. The German market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 11% over the same period.
Is New 90 Day High Low • Jan 14New 90-day high: €28.50The company is up 4.0% from its price of €27.40 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Biotechs industry, which is also up 4.0% over the same period.
Reported Earnings • Nov 13Third quarter 2020 earnings released: €0.39 loss per shareThe company reported a soft third quarter result with increased losses and weaker control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: €106.8m (up 7.0% from 3Q 2019). Net loss: €15.1m (loss widened 208% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.
Major Estimate Revision • Sep 25Analysts update estimatesThe company's losses in 2020 are expected to worsen with analysts lowering their consensus EPS forecasts from -€0.64 to -€0.72. Revenue estimate was approximately flat at €461.0m. The Biotechs industry in Germany is expected to see an average net income growth of 9.9% next year. The consensus price target increased from €24.10 to €31.20. Share price is down by 2.0% to €24.80 over the past week.
